MedTrace Logo

Racial Differences in Vagal Control of Glucose Homeostasis, Chronic Study

NCT03014323 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2018-08-13

No results posted yet for this study

Summary

Investigators will test the hypothesis that chronic restoration of vagal nerve activity with a central acetylcholinesterase inhibitor improves insulin sensitivity and reduces adipose tissue oxidation in obese African American Women compared to white women.

Conditions

  • Insulin Sensitivity
  • Oxidative Stress

Interventions

DRUG

Galantamine

Galantamine 4 mg twice a day for 4 weeks

DRUG

Placebo

Placebo 1 capsule twice a day for 4 weeks

Sponsors & Collaborators

  • Vanderbilt University Medical Center

    lead OTHER

Principal Investigators

  • Cyndya A Shibao, MD · Vanderbilt University Medical Center, Clinical Pharmacology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-01-31
Primary Completion
2018-11-30
Completion
2018-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03014323 on ClinicalTrials.gov